Published in Health Business Week, February 16th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Bioenvision.
Report 1: Bioenvision, Inc., (BIVN) has completed the substantive work and analysis involved with finalizing the Marketing Authorization Application (MAA) to expand the Evoltra (clofarabine) label and is now involved with the administrative aspects of formally submitting the filing to the European Medicines Agency (EMeA) for the use of Evoltra in adult AML patients over 65 years and who are considered unsuitable for intensive therapy.
The formal submission of the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.